Metamark Genetics has entered into development partnership with Definiens in which it will combine its proprietary multiplex detection platform with Definiens image analysis technology in order to deliver prognostic and predictive assays for early-stage cancers.
Metamark’s quantitative diagnostic approach identifies and account for small regions of molecular cancer cells within an otherwise indolent tumor.
It has also developed a portfolio of prognostic and predictive assays with the ability to address the ‘heterogeneous’ nature of tumors not only between one patient and the next, but also within an individual patient’s tumor.
Definiens has developed biomarker based on its scalable image analysis framework that enables scientists and clinicians to extract biomarker and morphology expression profiles and helps in identifying a subset of descriptors by correlating them against patient outcomes.
Definiens Sales & Operations vice president Thomas Colarusso said they believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays.